Hayward, CA – According to filings with the U.S. Securities and Exchange Commission, RefleXion Medical is raising $109,999,957.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Todd Powell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RefleXion Medical
RefleXion Medical is a biotargeting oncology company using each cancers unique biology as a means to reveal its location and then destroy it. Our journey began in 2009 with a simple question: if a cancer cell emits a signal, can we shoot right back to destroy it? Using biology to guide radiotherapy, we hope to have the means to turn cancer on itself. By leveraging positron emission tomography (PET), the gold standard in cancer imaging and staging in a novel way, RefleXions patented technology* causes tumors to continuously signal their location during radiotherapy delivery, potentially transforming radiotherapy from an early stage, local therapy into one suitable for metastatic disease. Were passionately committed to making dramatic changes to cancer care, and we believe that small, lean teams of brilliant people are the only way to do that. We need teammates with both the foresight and experience to avoid roadblocks, and the drive and creativity to steer around those that inevitably appear. We seek those who will unabashedly and relentlessly help us create a new modality in cancer care.

To learn more about RefleXion Medical, visit http://reflexion.com/

Contact:
Todd Powell, Chief Executive Officer
650-239-9070
todd@reflexion.com
https://www.linkedin.com/in/todd-powell/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved